Mode of action elucidation studies of new antimicrobial compounds [Master Thesis, TFM]
The World Health Organization estimates that, by 2050, 10 million people will die every year due to infections caused by bacteria resistant to current antimicrobial therapies. Among them, tuberculosis (TB), the deadliest infectious disease worldwide, killing 1.7 million people in 2017, is a global priority due to the emergence of MDR and XDR resistant strains. New compounds are urgently needed that are active against multi-drug resistant (MDR) bacteria. A critical step in the development process of these new drugs is to understand their molecular mode of action (MoA).
This Master Project will focus on the MoA elucidation of different new antimicrobial compounds.